长效可逆避孕措施：支持临床实践的新证据。
Long-acting reversible contraceptives: New evidence to support clinical practice.
机构信息
MBBS (Hons), FRACGP, GCertClinTeach, Senior Medical Education Officer, Sexual Health Victoria, Box Hill, Vic.
MBBS, DCH, FRACGP, Associate Medical Director, Family Planning NSW, Newington, NSW; Visiting Medical Officer, Department of Sexual Assault Service, Royal North Shore Hospital, St Leonards, NSW.
出版信息
Aust J Gen Pract. 2022 Apr;51(4):246-252. doi: 10.31128/AJGP-03-21-5908.
BACKGROUND
General practice plays a key role in providing access to contraceptive options to reduce unintended pregnancies. The use of long-acting reversible contraceptives (LARCs) is increasing in Australia.
OBJECTIVE
The aim of this article is to provide an update on new evidence and guidance relating to clinical practice for LARCs.
DISCUSSION
A new Pharmaceutical Benefits Scheme-listed hormonal intrauterine device (IUD), as well as updated guidelines for LARC provision and use, are reviewed. The 19.5 mg levonorgestrel IUD provides a smaller, lower-dose hormonal IUD. This article compares IUDs now available in Australia to support informed patient choice. Updated guidance for IUD users in perimenopause, as well as those using menstrual cups, is outlined. The contraceptive hormonal implant has updated product information, which includes new insertion site and arm positioning for procedures.
背景
全科医疗在提供避孕选择以减少意外怀孕方面发挥着关键作用。长效可逆避孕药（LARCs）在澳大利亚的使用正在增加。
目的
本文旨在提供有关 LARCs 临床实践的新证据和新指南。
讨论
审查了一种新的药品福利计划（PBS）清单激素宫内节育器（IUD），以及 LARC 提供和使用的更新指南。19.5 毫克左炔诺孕酮宫内节育器提供了一种更小、更低剂量的激素宫内节育器。本文比较了澳大利亚目前可用的 IUD，以支持知情的患者选择。概述了围绝经期和使用月经杯的 IUD 用户的更新指南。避孕激素植入物具有更新的产品信息，包括新的插入部位和手臂定位。
Zotero 插件